Venous thromboembolism (VTE) is a leading cause of morbidity and mortality among cancer patients. They develop more VTE than those without cancer and experience higher rates of VTE recurrence and haemorrhagic complications [1] that vary depending on patient-related risk factors, tumour site, cancer stage, and anticancer treatments [2].
